Clinical trial
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous…
NCT00295763 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00295763 |
|---|---|
| Title | A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. |
| Official title | Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Differentiated Thyroid Cancer |
| Intervention type | Drug |
| Interventions | Thyrogen (thyrotropin alfa for injection) |
| Enrollment | 61 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Feb 24, 2006 |
| Last update posted | Mar 18, 2015 |
| Countries | Canada, France, Germany, Italy, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: